| 000 | 01909 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517165510.0 | ||
| 264 | 0 | _c20170908 | |
| 008 | 201709s 0 0 eng d | ||
| 022 | _a1464-3405 | ||
| 024 | 7 |
_a10.1016/j.bmcl.2017.07.052 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDing, Xiao | |
| 245 | 0 | 0 |
_aDiscovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry letters _c09 2017 |
||
| 300 |
_a4034-4038 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aBenzamides _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Discovery |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeucine-Rich Repeat Serine-Threonine Protein Kinase-2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMolecular Structure |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aDai, Xuedong | |
| 700 | 1 | _aLong, Kai | |
| 700 | 1 | _aPeng, Cheng | |
| 700 | 1 | _aAndreotti, Daniele | |
| 700 | 1 | _aBamborough, Paul | |
| 700 | 1 | _aEatherton, Andrew J | |
| 700 | 1 | _aEdge, Colin | |
| 700 | 1 | _aJandu, Karamjit S | |
| 700 | 1 | _aNichols, Paula L | |
| 700 | 1 | _aPhilps, Oliver J | |
| 700 | 1 | _aStasi, Luigi Piero | |
| 700 | 1 | _aWan, Zehong | |
| 700 | 1 | _aXiang, Jia-Ning | |
| 700 | 1 | _aDong, Kelly | |
| 700 | 1 | _aDossang, Pamela | |
| 700 | 1 | _aHo, Ming-Hsun | |
| 700 | 1 | _aLi, Yi | |
| 700 | 1 | _aMensah, Lucy | |
| 700 | 1 | _aGuan, Xiaoming | |
| 700 | 1 | _aReith, Alastair D | |
| 700 | 1 | _aRen, Feng | |
| 773 | 0 |
_tBioorganic & medicinal chemistry letters _gvol. 27 _gno. 17 _gp. 4034-4038 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bmcl.2017.07.052 _zAvailable from publisher's website |
| 999 |
_c27432555 _d27432555 |
||